Details of the Drug

General Information of Drug (ID: DM30SGU)

Drug Name

Simvastatin

Synonyms

Cholestat; Coledis; Colemin; Corolin; Denan; Labistatin; Lipex; Lipovas; Lodales; Medipo; Nivelipol; Pantok; Rendapid; Simovil; Simvastatina; Simvastatine; Simvastatinum; Sinvacor; Sivastin; Synvinolin; Vasotenal; Zocor; Zocord; Simvast CR; Simvastatina [Spanish]; Simvastatine [French]; Simvastatinum [Latin]; MK 0733; MK 733; MK733; TNP00259; DRG-0320; KS-1113; L 644128-000U; MK-0733; MK-733; Simcard (TN); Simlup (TN); Simvacor (TN); Simvastatin & Primycin; Simvastatin, Compactin; Zocor (TN); Simvastatin [USAN:INN:BAN]; Simvastatin (JAN/USP/INN); Zocor, Simlup, Simcard, Simvacor, Simvoget, Zorced, Simvastatin; [(1S,3R,7S,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] 2,2-dimethylbutanoate; Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester; Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-((2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester; Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,*aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-((2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester; (1S,3R,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2,2-dimethylbutanoate; Butanoic acid, 2,2-dimethyl-,1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)-ethyl]-1-naphthalenyl ester, [1S-[1 alpha,3 alpha,7 beta,8 beta(2S*,4S*),-8a beta; 2,2-Dimethylbutanoic acid (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester; 2,2-Dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one

Indication

Disease Entry	ICD 11	Status	REF
Arteriosclerosis	BD40	Approved	[1]
Atherosclerosis	BD40	Approved	[1]
Coronary heart disease	BA80.Z	Approved	[1]
Cystic fibrosis	CA25	Approved	[1]
Depression	6A70-6A7Z	Approved	[1]
Hypercholesterolaemia	5C80.0	Approved	[2]
Hyperlipidemia	5C80.Z	Approved	[1]
Hyperlipidemia, familial combined, LPL related	N.A.	Approved	[1]
Hypertriglyceridemia	5C80.1	Approved	[1]
Pneumonia	CA40	Approved	[1]
Primary hypercholesterolemia	5C80.00	Approved	[1]
Prostate carcinoma	N.A.	Approved	[1]
Rhinitis	FA20	Approved	[1]
Type-1/2 diabetes	5A10-5A11	Approved	[1]
Stroke	8B20	Investigative	[1]
------------------------------------------------------------------------------------


⏷ Show the Full List of Indication(s)

Therapeutic Class

Anticholesteremic Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

418.6

Logarithm of the Partition Coefficient (xlogp)

4.7

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption Tmax: The time to maximum plasma concentration (Tmax) is 1.3-2.4 h [3]
BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [4]
Elimination: 13% of the dose was excreted in urine and 60% in feces []
Half-life: The concentration or amount of drug in body reduced by one-half in 4.85 hours [3]
Metabolism: The drug is metabolized via a combination of spontaneous chemical conversion and enzyme-mediated hydrolysis by nonspecific carboxyesterases in the intestinal wall, liver, and plasma [5]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 1.3652 micromolar/kg/day [6]
Water Solubility: The ability of drug to dissolve in water is measured as 0.03 mg/mL [4]

Adverse Drug Reaction (ADR)

ADR Term	Variation	Related DOT	DOT ID	REF
Acute myocardial infarction	Not Available	MMP3	OTGBI74Z	[7]
Arteriosclerosis	Not Available	CES1	OT9L0LR8	[7]
Cardiovascular disorder	rs20455	KIF6	OTDH3MR4	[8]
-----------

Chemical Identifiers

Formula: C25H38O5
IUPAC Name: [(1S,3R,7S,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] 2,2-dimethylbutanoate
Canonical SMILES: CCC(C)(C)C(=O)O[C@H]1C[C@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@@H]3C[C@H](CC(=O)O3)O)C
InChI: InChI=1S/C25H38O5/c1-6-25(4,5)24(28)30-21-12-15(2)11-17-8-7-16(3)20(23(17)21)10-9-19-13-18(26)14-22(27)29-19/h7-8,11,15-16,18-21,23,26H,6,9-10,12-14H2,1-5H3/t15-,16-,18+,19+,20-,21-,23-/m0/s1
InChIKey: RYMZZMVNJRMUDD-HGQWONQESA-N

Cross-matching ID

PubChem CID: 54454
ChEBI ID: CHEBI:9150
CAS Number: 79902-63-9
DrugBank ID: DB00641
TTD ID: D0H0ND
VARIDT ID: DR00435
INTEDE ID: DR1485
ACDINA ID: D00625

Combinatorial Drugs (CBD)

Click to Jump to the Detailed CBD Information of This Drug

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
HMG-CoA reductase (HMGCR)	TTPADOQ	HMDH_HUMAN	Inhibitor	[9]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Breast cancer resistance protein (ABCG2)	DTI7UX6	ABCG2_HUMAN	Substrate	[10]
Organic anion transporting polypeptide 1B1 (SLCO1B1)	DT3D8F0	SO1B1_HUMAN	Substrate	[11]
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[12]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)_{Main DME}	DE4LYSA	CP3A4_HUMAN	Substrate	[13]
Cytochrome P450 2D6 (CYP2D6)	DECB0K3	CP2D6_HUMAN	Substrate	[14]
UDP-glucuronosyltransferase 1A1 (UGT1A1)	DEYGVN4	UD11_HUMAN	Substrate	[15]
Mephenytoin 4-hydroxylase (CYP2C19)	DEGTFWK	CP2CJ_HUMAN	Substrate	[15]
Cytochrome P450 3A5 (CYP3A5)_{Main DME}	DEIBDNY	CP3A5_HUMAN	Substrate	[16]
Cytochrome P450 2C8 (CYP2C8)	DES5XRU	CP2C8_HUMAN	Substrate	[17]
UDP-glucuronosyltransferase 2B7 (UGT2B7)	DEB3CV1	UD2B7_HUMAN	Substrate	[15]
UDP-glucuronosyltransferase 1A3 (UGT1A3)	DEF2WXN	UD13_HUMAN	Substrate	[15]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-2 (PLCG2)	OTGVC9MY	PLCG2_HUMAN	Gene/Protein Processing	[18]
3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR)	OTRT3F3U	HMDH_HUMAN	Drug Response	[19]
5-hydroxytryptamine receptor 3B (HTR3B)	OTMGIYRE	5HT3B_HUMAN	Drug Response	[20]
5-hydroxytryptamine receptor 7 (HTR7)	OT44DEWB	5HT7R_HUMAN	Drug Response	[20]
7-dehydrocholesterol reductase (DHCR7)	OTLILBUI	DHCR7_HUMAN	Gene/Protein Processing	[21]
72 kDa type IV collagenase (MMP2)	OT5NIWA2	MMP2_HUMAN	Gene/Protein Processing	[22]
Advanced glycosylation end product-specific receptor (AGER)	OTPY0IH7	RAGE_HUMAN	Gene/Protein Processing	[23]
Aldehyde dehydrogenase, dimeric NADP-preferring (ALDH3A1)	OTAYZZE6	AL3A1_HUMAN	Gene/Protein Processing	[18]
Aldo-keto reductase family 1 member C1 (AKR1C1)	OTQKR4CM	AK1C1_HUMAN	Gene/Protein Processing	[18]
Aldo-keto reductase family 1 member C3 (AKR1C3)	OTU2SXBA	AK1C3_HUMAN	Gene/Protein Processing	[24]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Arteriosclerosis

ICD Disease Classification

BD40

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
HMG-CoA reductase (HMGCR)	DTT	HMGCR	1.01E-05	0.65	1.53
P-glycoprotein 1 (ABCB1)	DTP	P-GP	3.29E-14	-7.08E-01	-1.99E+00
Breast cancer resistance protein (ABCG2)	DTP	BCRP	2.28E-08	-3.66E-01	-8.07E-01
Organic anion transporting polypeptide 1B1 (SLCO1B1)	DTP	OATP1B1	3.27E-01	-5.78E-02	-3.84E-01
UDP-glucuronosyltransferase 1A1 (UGT1A1)	DME	UGT1A1	2.00E-01	5.79E-02	3.00E-01
Cytochrome P450 2C8 (CYP2C8)	DME	CYP2C8	1.47E-02	-1.13E-01	-1.13E+00
Cytochrome P450 3A5 (CYP3A5)	DME	CYP3A5	3.65E-02	-8.90E-02	-5.58E-01
Mephenytoin 4-hydroxylase (CYP2C19)	DME	CYP2C19	4.03E-02	-1.19E-01	-5.11E-01
Cytochrome P450 2D6 (CYP2D6)	DME	CYP2D6	5.05E-04	-1.51E-01	-8.87E-01
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	3.24E-05	-3.48E-01	-1.34E+00

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Simvastatin

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Mipomersen	DMGSRN1	Major	Increased risk of hepatotoxicity by the combination of Simvastatin and Mipomersen.	Hyper-lipoproteinaemia [5C80]	[25]
Teriflunomide	DMQ2FKJ	Major	Increased risk of hepatotoxicity by the combination of Simvastatin and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[26]
BMS-201038	DMQTAGO	Major	Decreased metabolism of Simvastatin caused by BMS-201038 mediated inhibition of CYP450 enzyme.	Hyper-lipoproteinaemia [5C80]	[27]
-----------

Coadministration of a Drug Treating the Disease Different from Simvastatin (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Remdesivir	DMBFZ6L	Moderate	Increased risk of hepatotoxicity by the combination of Simvastatin and Remdesivir.	1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019]	[28]
Ivosidenib	DM8S6T7	Moderate	Increased metabolism of Simvastatin caused by Ivosidenib mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[29]
Midostaurin	DMI6E0R	Moderate	Decreased clearance of Simvastatin due to the transporter inhibition by Midostaurin.	Acute myeloid leukaemia [2A60]	[30]
Arn-509	DMT81LZ	Moderate	Increased metabolism of Simvastatin caused by Arn-509 mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[30]
Emapalumab	DMZG5WL	Moderate	Altered metabolism of Simvastatin due to Emapalumab alters the formation of CYP450 enzymes.	Adaptive immunity immunodeficiency [4A01]	[30]
Siltuximab	DMGEATB	Moderate	Altered metabolism of Simvastatin due to Siltuximab alters the formation of CYP450 enzymes.	Anemia [3A00-3A9Z]	[30]
Dronedarone	DMA8FS5	Major	Decreased clearance of Simvastatin due to the transporter inhibition by Dronedarone.	Angina pectoris [BA40]	[31]
Nifedipine	DMSVOZT	Moderate	Decreased metabolism of Simvastatin caused by Nifedipine mediated inhibition of CYP450 enzyme.	Angina pectoris [BA40]	[32]
Bedaquiline	DM3906J	Moderate	Increased risk of hepatotoxicity by the combination of Simvastatin and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[33]
Posaconazole	DMUL5EW	Major	Decreased metabolism of Simvastatin caused by Posaconazole mediated inhibition of CYP450 enzyme.	Aspergillosis [1F20]	[28]
Dalfopristin	DM4LTKV	Moderate	Decreased metabolism of Simvastatin caused by Dalfopristin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[34]
Clarithromycin	DM4M1SG	Major	Decreased metabolism of Simvastatin caused by Clarithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[35]
Troleandomycin	DMUZNIG	Major	Decreased metabolism of Simvastatin caused by Troleandomycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[35]
Telithromycin	DMZ4P3A	Major	Decreased metabolism of Simvastatin caused by Telithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[36]
Ag-221	DMS0ZBI	Moderate	Decreased clearance of Simvastatin due to the transporter inhibition by Ag-221.	BCR-ABL1-negative chronic myeloid leukaemia [2A41]	[28]
Erdafitinib	DMI782S	Moderate	Increased metabolism of Simvastatin caused by Erdafitinib mediated induction of CYP450 enzyme.	Bladder cancer [2C94]	[37]
Pexidartinib	DMS2J0Z	Major	Increased risk of hepatotoxicity by the combination of Simvastatin and Pexidartinib.	Bone/articular cartilage neoplasm [2F7B]	[38]
Talazoparib	DM1KS78	Moderate	Decreased clearance of Simvastatin due to the transporter inhibition by Talazoparib.	Breast cancer [2C60-2C6Y]	[39]
Lapatinib	DM3BH1Y	Moderate	Decreased metabolism of Simvastatin caused by Lapatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[32]
Tucatinib	DMBESUA	Major	Decreased metabolism of Simvastatin caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[40]
Palbociclib	DMD7L94	Moderate	Decreased metabolism of Simvastatin caused by Palbociclib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[32]
Anisindione	DM2C48U	Minor	Increased plasma concentration of Simvastatin and Anisindione due to competitive binding of plasma proteins.	Coagulation defect [3B10]	[41]
Mifepristone	DMGZQEF	Major	Decreased metabolism of Simvastatin caused by Mifepristone mediated inhibition of CYP450 enzyme.	Cushing syndrome [5A70]	[42]
Osilodrostat	DMIJC9X	Moderate	Decreased metabolism of Simvastatin caused by Osilodrostat mediated inhibition of CYP450 enzyme.	Cushing syndrome [5A70]	[32]
Lumacaftor	DMCLWDJ	Major	Increased metabolism of Simvastatin caused by Lumacaftor mediated induction of CYP450 enzyme.	Cystic fibrosis [CA25]	[28]
Ivacaftor	DMZC1HS	Moderate	Decreased clearance of Simvastatin due to the transporter inhibition by Ivacaftor.	Cystic fibrosis [CA25]	[43]
MK-8228	DMOB58Q	Major	Decreased clearance of Simvastatin due to the transporter inhibition by MK-8228.	Cytomegaloviral disease [1D82]	[44]
Aprepitant	DM053KT	Moderate	Decreased metabolism of Simvastatin caused by Aprepitant mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[32]
Nefazodone	DM4ZS8M	Major	Decreased metabolism of Simvastatin caused by Nefazodone mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[40]
Oxcarbazepine	DM5PU6O	Moderate	Increased metabolism of Simvastatin caused by Oxcarbazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[45]
Stiripentol	DMMSDOY	Moderate	Decreased metabolism of Simvastatin caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[46]
Rufinamide	DMWE60C	Moderate	Increased metabolism of Simvastatin caused by Rufinamide mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[30]
Eslicarbazepine	DMZREFQ	Moderate	Increased metabolism of Simvastatin caused by Eslicarbazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[30]
Cannabidiol	DM0659E	Moderate	Increased risk of hepatotoxicity by the combination of Simvastatin and Cannabidiol.	Epileptic encephalopathy [8A62]	[30]
Itraconazole	DMCR1MV	Major	Decreased metabolism of Simvastatin caused by Itraconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[26]
Miconazole	DMPMYE8	Moderate	Decreased metabolism of Simvastatin caused by Miconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[30]
Ketoconazole	DMPZI3Q	Major	Decreased metabolism of Simvastatin caused by Ketoconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[47]
Boceprevir	DMBSHMF	Major	Decreased metabolism of Simvastatin caused by Boceprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[35]
Simeprevir	DMLUA9D	Moderate	Decreased clearance of Simvastatin due to the transporter inhibition by Simeprevir.	Hepatitis virus infection [1E50-1E51]	[48]
Telaprevir	DMMRV29	Major	Decreased metabolism of Simvastatin caused by Telaprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[35]
Rifampin	DMA8J1G	Major	Increased metabolism of Simvastatin caused by Rifampin mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[49]
Rifapentine	DMCHV4I	Moderate	Increased metabolism of Simvastatin caused by Rifapentine mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[50]
Brentuximab vedotin	DMWLC57	Moderate	Increased risk of hepatotoxicity by the combination of Simvastatin and Brentuximab vedotin.	Hodgkin lymphoma [2B30]	[51]
Delavirdine	DM3NF5G	Major	Decreased metabolism of Simvastatin caused by Delavirdine mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[52]
Fosamprenavir	DM4W9B3	Major	Decreased metabolism of Simvastatin caused by Fosamprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[53]
Fostemsavir	DM50ILT	Moderate	Decreased clearance of Simvastatin due to the transporter inhibition by Fostemsavir.	Human immunodeficiency virus disease [1C60-1C62]	[54]
Cobicistat	DM6L4H2	Major	Decreased metabolism of Simvastatin caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[40]
Tipranavir	DM8HJX6	Major	Decreased metabolism of Simvastatin caused by Tipranavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[53]
Saquinavir	DMG814N	Major	Decreased metabolism of Simvastatin caused by Saquinavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[53]
Etravirine	DMGV8QU	Moderate	Increased metabolism of Simvastatin caused by Etravirine mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[55]
Zalcitabine	DMH7MUV	Moderate	Increased risk of peripheral neuropathy by the combination of Simvastatin and Zalcitabine.	Human immunodeficiency virus disease [1C60-1C62]	[56]
Amprenavir	DMLMXE0	Major	Decreased metabolism of Simvastatin caused by Amprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[53]
Darunavir	DMN3GCH	Major	Decreased metabolism of Simvastatin caused by Darunavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[53]
Atazanavir	DMSYRBX	Major	Decreased metabolism of Simvastatin caused by Atazanavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[53]
Levamlodipine	DM92S6N	Major	Decreased metabolism of Simvastatin caused by Levamlodipine mediated inhibition of CYP450 enzyme.	Hypertension [BA00-BA04]	[57]
Conivaptan	DM1V329	Major	Decreased metabolism of Simvastatin caused by Conivaptan mediated inhibition of CYP450 enzyme.	Hypo-osmolality/hyponatraemia [5C72]	[35]
Lesinurad	DMUR64T	Moderate	Increased metabolism of Simvastatin caused by Lesinurad mediated induction of CYP450 enzyme.	Inborn purine/pyrimidine/nucleotide metabolism error [5C55]	[58]
Berotralstat	DMWA2DZ	Moderate	Decreased metabolism of Simvastatin caused by Berotralstat mediated inhibition of CYP450 enzyme.	Innate/adaptive immunodeficiency [4A00]	[32]
Suvorexant	DM0E6S3	Moderate	Decreased metabolism of Simvastatin caused by Suvorexant mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[32]
Crizotinib	DM4F29C	Moderate	Decreased metabolism of Simvastatin caused by Crizotinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[32]
Brigatinib	DM7W94S	Moderate	Increased metabolism of Simvastatin caused by Brigatinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[59]
Porfimer Sodium	DM7ZWNY	Moderate	Increased risk of photosensitivity reactions by the combination of Simvastatin and Porfimer Sodium.	Lung cancer [2C25]	[60]
Ceritinib	DMB920Z	Major	Decreased metabolism of Simvastatin caused by Ceritinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[40]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Simvastatin caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[61]
Osimertinib	DMRJLAT	Moderate	Increased metabolism of Simvastatin caused by Osimertinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[30]
Selpercatinib	DMZR15V	Moderate	Decreased metabolism of Simvastatin caused by Selpercatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[32]
Calaspargase pegol	DMQZBXI	Moderate	Increased risk of hepatotoxicity by the combination of Simvastatin and Calaspargase pegol.	Malignant haematopoietic neoplasm [2B33]	[62]
Idelalisib	DM602WT	Major	Decreased metabolism of Simvastatin caused by Idelalisib mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[40]
IPI-145	DMWA24P	Moderate	Decreased metabolism of Simvastatin caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[32]
Arry-162	DM1P6FR	Moderate	Decreased clearance of Simvastatin due to the transporter inhibition by Arry-162.	Melanoma [2C30]	[28]
LGX818	DMNQXV8	Moderate	Increased metabolism of Simvastatin caused by LGX818 mediated induction of CYP450 enzyme.	Melanoma [2C30]	[63]
Dabrafenib	DMX6OE3	Moderate	Decreased clearance of Simvastatin due to the transporter inhibition by Dabrafenib.	Melanoma [2C30]	[28]
Danazol	DML8KTN	Major	Decreased metabolism of Simvastatin caused by Danazol mediated inhibition of CYP450 enzyme.	Menstrual cycle bleeding disorder [GA20]	[34]
Exjade	DMHPRWG	Moderate	Decreased metabolism of Simvastatin caused by Exjade mediated inhibition of CYP450 enzyme.	Mineral absorption/transport disorder [5C64]	[64]
Thalidomide	DM70BU5	Moderate	Increased risk of peripheral neuropathy by the combination of Simvastatin and Thalidomide.	Multiple myeloma [2A83]	[56]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Simvastatin caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[32]
Dasatinib	DMJV2EK	Moderate	Decreased metabolism of Simvastatin caused by Dasatinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[32]
Modafinil	DMYILBE	Moderate	Increased metabolism of Simvastatin caused by Modafinil mediated induction of CYP450 enzyme.	Narcolepsy [7A20]	[28]
Netupitant	DMEKAYI	Moderate	Decreased metabolism of Simvastatin caused by Netupitant mediated inhibition of CYP450 enzyme.	Nausea/vomiting [MD90]	[34]
Entrectinib	DMMPTLH	Moderate	Decreased metabolism of Simvastatin caused by Entrectinib mediated inhibition of CYP450 enzyme.	Non-small cell lung cancer [2C25]	[32]
Olaparib	DM8QB1D	Moderate	Decreased metabolism of Simvastatin caused by Olaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[28]
Rucaparib	DM9PVX8	Moderate	Decreased metabolism of Simvastatin caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[32]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Simvastatin caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[65]
Esomeprazole	DM7BN0X	Moderate	Increased plasma concentrations of Simvastatin and Esomeprazole due to competitive inhibition of the same metabolic pathway.	Peptic ulcer [DA61]	[49]
Lefamulin	DME6G97	Moderate	Decreased metabolism of Simvastatin caused by Lefamulin mediated inhibition of CYP450 enzyme.	Pneumonia [CA40]	[66]
Lonafarnib	DMGM2Z6	Major	Decreased metabolism of Simvastatin caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[67]
Enzalutamide	DMGL19D	Moderate	Increased metabolism of Simvastatin caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[68]
Darolutamide	DMV7YFT	Moderate	Decreased clearance of Simvastatin due to the transporter inhibition by Darolutamide.	Prostate cancer [2C82]	[30]
Bicalutamide	DMZMSPF	Moderate	Decreased metabolism of Simvastatin caused by Bicalutamide mediated inhibition of CYP450 enzyme.	Prostate cancer [2C82]	[32]
Ustekinumab	DMHTYK3	Moderate	Altered metabolism of Simvastatin due to Ustekinumab alters the formation of CYP450 enzymes.	Psoriasis [EA90]	[30]
Ixekizumab	DMXW92T	Moderate	Altered metabolism of Simvastatin due to Ixekizumab alters the formation of CYP450 enzymes.	Psoriasis [EA90]	[30]
Tocilizumab	DM7J6OR	Moderate	Altered metabolism of Simvastatin due to Tocilizumab alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[30]
Canakinumab	DM8HLO5	Moderate	Altered metabolism of Simvastatin due to Canakinumab alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[30]
Rilonacept	DMGLUQS	Moderate	Altered metabolism of Simvastatin due to Rilonacept alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[30]
Sarilumab	DMOGNXY	Moderate	Altered metabolism of Simvastatin due to Sarilumab alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[30]
Leflunomide	DMR8ONJ	Major	Increased risk of hepatotoxicity by the combination of Simvastatin and Leflunomide.	Rheumatoid arthritis [FA20]	[26]
Voxelotor	DMCS6M5	Moderate	Decreased metabolism of Simvastatin caused by Voxelotor mediated inhibition of CYP450 enzyme.	Sickle-cell disorder [3A51]	[32]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Simvastatin caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[30]
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Simvastatin caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[32]
Armodafinil	DMGB035	Moderate	Increased metabolism of Simvastatin caused by Armodafinil mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[28]
LEE011	DMMX75K	Moderate	Decreased metabolism of Simvastatin caused by LEE011 mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[32]
Naltrexone	DMUL45H	Moderate	Increased risk of hepatotoxicity by the combination of Simvastatin and Naltrexone.	Substance abuse [6C40]	[69]
Warfarin	DMJYCVW	Minor	Increased plasma concentration of Simvastatin and Warfarin due to competitive binding of plasma proteins.	Supraventricular tachyarrhythmia [BC81]	[41]
Fostamatinib	DM6AUHV	Moderate	Decreased metabolism of Simvastatin caused by Fostamatinib mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[70]
Lusutrombopag	DMH6IKO	Moderate	Decreased clearance of Simvastatin due to the transporter inhibition by Lusutrombopag.	Thrombocytopenia [3B64]	[71]
Brilinta	DMBR01X	Moderate	Decreased metabolism of Simvastatin caused by Brilinta mediated inhibition of CYP450 enzyme.	Thrombosis [DB61-GB90]	[30]
Sirolimus	DMGW1ID	Moderate	Increased plasma concentrations of Simvastatin and Sirolimus due to competitive inhibition of the same metabolic pathway.	Transplant rejection [NE84]	[72]
Tacrolimus	DMZ7XNQ	Moderate	Increased plasma concentrations of Simvastatin and Tacrolimus due to competitive inhibition of the same metabolic pathway.	Transplant rejection [NE84]	[72]
Albiglutide	DM1JEGF	Minor	Altered absorption of Simvastatin due to GI dynamics variation caused by Albiglutide.	Type 2 diabetes mellitus [5A11]	[46]
Dapagliflozin	DM28UJG	Minor	Increased plasma concentrations of Simvastatin and Dapagliflozin due to competitive inhibition of the same metabolic pathway.	Type 2 diabetes mellitus [5A11]	[73]
Amiodarone	DMUTEX3	Major	Decreased metabolism of Simvastatin caused by Amiodarone mediated inhibition of CYP450 enzyme.	Ventricular tachyarrhythmia [BC71]	[74]
-----------


⏷ Show the Full List of 111 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Allura red AC dye	E00338	33258	Colorant
Calcium ascorbate anhydrous	E00582	54740489	Antioxidant
Isopropyl alcohol	E00070	3776	Antimicrobial preservative; Solvent
Kyselina citronova	E00014	311	Acidulant; Antioxidant; Buffering agent; Complexing agent; Flavoring agent
Ascorbic acid	E00579	54670067	Acidulant; Antioxidant
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Butylhydroxyanisole	E00308	24667	Antimicrobial preservative; Antioxidant
Carmellose sodium	E00625	Not Available	Disintegrant
Citric acid monohydrate	E00271	22230	Acidulant; Antioxidant; Buffering agent; Complexing agent; Flavoring agent
Eisenoxyd	E00585	56841934	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Hypromellose	E00634	Not Available	Coating agent
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Polyethylene glycol 3350	E00652	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 4000	E00654	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Triacetin	E00080	5541	Humectant; Plasticizing agent; Solvent
Triethyl citrate	E00128	6506	Plasticizing agent; Solvent
--------------------


⏷ Show the Full List of 23 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Simvastatin 80 mg tablet	80 mg	Oral Tablet	Oral
Simvastatin 10 mg tablet	10 mg	Oral Tablet	Oral
Simvastatin 40 mg tablet	40 mg	Oral Tablet	Oral
Simvastatin 20 mg tablet	20 mg	Oral Tablet	Oral
Simvastatin 5 mg tablet	5 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	Simvastatin FDA Label
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2955).
3	Simvastatin pharmacokinetics in healthy Chinese subjects and its relations with CYP2C9, CYP3A5, ABCB1, ABCG2 and SLCO1B1 polymorphisms. Pharmazie. 2013 Feb;68(2):124-8.
4	BDDCS applied to over 900 drugs
5	Nakajima M, Nakamura S, Tokudome S, Shimada N, Yamazaki H, Yokoi T: Azelastine N-demethylation by cytochrome P-450 (CYP)3A4, CYP2D6, and CYP1A2 in human liver microsomes: evaluation of approach to predict the contribution of multiple CYPs. Drug Metab Dispos. 1999 Dec;27(12):1381-91.
6	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7	ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
8	Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: the CARE and WOSCOPS trials. J Am Coll Cardiol. 2008 Jan 29;51(4):435-43. doi: 10.1016/j.jacc.2007.05.057.
9	Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes. Biopharm Drug Dispos. 2000 Dec;21(9):353-64.
10	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
11	Impact of OATP transporters on pharmacokinetics. Br J Pharmacol. 2009 Oct;158(3):693-705.
12	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
13	A comparison of the effects of 3-hydroxy-3-methylglutaryl-coenzyme a (HMG-CoA) reductase inhibitors on the CYP3A4-dependent oxidation of mexazolam in vitro. Drug Metab Dispos. 2001 Mar;29(3):282-8.
14	Genetic polymorphisms in cytochrome P450 enzymes: effect on efficacy and tolerability of HMG-CoA reductase inhibitors. Am J Cardiovasc Drugs. 2004;4(4):247-55.
15	Pharmacogenomics of statins: understanding susceptibility to adverse effects. Pharmgenomics Pers Med. 2016 Oct 3;9:97-106.
16	In vitro metabolism of simvastatin in humans [SBT]identification of metabolizing enzymes and effect of the drug on hepatic P450s. Drug Metab Dispos. 1997 Oct;25(10):1191-9.
17	Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther. 2006 Dec;80(6):565-81.
18	Simvastatin inactivates beta1-integrin and extracellular signal-related kinase signaling and inhibits cell proliferation in head and neck squamous cell carcinoma cells. Cancer Sci. 2007 Jun;98(6):890-9.
19	Alternative splicing of 3-hydroxy-3-methylglutaryl coenzyme A reductase is associated with plasma low-density lipoprotein cholesterol response to simvastatin. Circulation. 2008 Jul 22;118(4):355-62. doi: 10.1161/CIRCULATIONAHA.108.773267. Epub 2008 Jun 16.
20	Physiogenomic association of statin-related myalgia to serotonin receptors. Muscle Nerve. 2007 Sep;36(3):329-35. doi: 10.1002/mus.20871.
21	Hydroxychloroquine decreases human MSC-derived osteoblast differentiation and mineralization in vitro. J Cell Mol Med. 2018 Feb;22(2):873-882. doi: 10.1111/jcmm.13373. Epub 2017 Oct 3.
22	Impaired migration of trophoblast cells caused by simvastatin is associated with decreased membrane IGF-I receptor, MMP2 activity and HSP27 expression. Hum Reprod. 2007 Apr;22(4):1161-7. doi: 10.1093/humrep/del464. Epub 2006 Dec 11.
23	Suppression of RAGE as a basis of simvastatin-dependent plaque stabilization in type 2 diabetes. Arterioscler Thromb Vasc Biol. 2006 Dec;26(12):2716-23.
24	In-vivo effects of simvastatin and rosuvastatin on global gene expression in peripheral blood leucocytes in a human inflammation model. Pharmacogenet Genomics. 2008 Feb;18(2):109-20.
25	Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
26	Canadian Pharmacists Association.
27	Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
28	Cerner Multum, Inc. "Australian Product Information.".
29	Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
30	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
31	Holtzman CW, Wiggins BS, Spinler SA "Role of P-glycoprotein in statin drug interactions." Pharmacotherapy 26 (2006): 1601-7. [PMID: 17064205]
32	Agbin NE, Brater DC, Hall SD "Interaction of diltiazem with lovastatin and pravastatin." Clin Pharmacol Ther 61 (1997): 201. [PMID: 9797793]
33	Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
34	Andreou ER, Ledger S "Potential drug interaction between simvastatin and danazol causing rhabdomyolysis." Can J Clin Pharmacol 10 (2003): 172-4. [PMID: 14712320]
35	Ayanian JZ, Fuchs CS, Stone RM "Lovastatin and rhabdomyolysis." Ann Intern Med 109 (1988): 682-3. [PMID: 3421582]
36	Product Information. Ketek (telithromycin). Aventis Pharmaceuticals, Bridgewater, NJ.
37	Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
38	Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
39	Product Information. Talzenna (talazoparib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
40	Alderman CP "Possible interaction between nefazodone and pravastatin." Ann Pharmacother 33 (1999): 871. [PMID: 10466919]
41	Gaw A, Wosornu D "Simvastatin during warfarin therapy in hyperlipoproteinaemia." Lancet 340 (1992): 979-80. [PMID: 1357387]
42	He K, Woolf TF, Hollenberg PF "Mechanism-based inactivation of cytochrome P-450-3A4 by mifepristone (RU486)." J Pharmacol Exp Ther 288 (1999): 791-7. [PMID: 9918590]
43	Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
44	Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
45	Product Information. Trileptal (oxcarbazepine) Novartis Pharmaceuticals, East Hanover, NJ.
46	EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
47	Akram K, Rao S, Parker M "A lesson for everyone in drug-drug interactions." Int J Cardiol 118 (2007): e19-20. [PMID: 17368833]
48	Product Information. Olysio (simeprevir). Janssen Pharmaceuticals, Titusville, NJ.
49	Bogman K, Peyer AK, Torok M, Kusters E, Drewe J "HMG-CoA reductase inhibitors and P-glycoprotein modulation." Br J Pharmacol 132 (2001): 1183-92. [PMID: 11250868]
50	Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
51	Product Information. Accolate (zafirlukast). Zeneca Pharmaceuticals, Wilmington, DE.
52	Product Information. Rescriptor (delavirdine). Pharmacia and Upjohn, Kalamazoo, MI.
53	Barry M, Mulcahy F, Merry C, Gibbons S, Back D "Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection." Clin Pharmacokinet 36 (1999): 289-304. [PMID: 10320951]
54	Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
55	Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
56	Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6. [PMID: 219931]
57	Product Information. Zocor (simvastatin). Merck & Co, Inc, West Point, PA.
58	Product Information. Zurampic (lesinurad). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
59	Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
60	Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivity-an update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47. [PMID: 30888626]
61	Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
62	Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
63	Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
64	Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
65	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
66	Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
67	Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
68	Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
69	Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.
70	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
71	EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
72	Barshes NR, Goodpastor SE, Goss JA "Sirolimus-atorvastatin drug interaction in the pancreatic islet transplant recipient." Transplantation 76 (2003): 1649-50. [PMID: 14702546]
73	Product Information. Farxiga (dapagliflozin). Bristol-Myers Squibb, Princeton, NJ.
74	Chouhan UM, Chakrabarti S, Millward LJ "Simvastatin interaction with clarithromycin and amiodarone causing myositis." Ann Pharmacother 39 (2005): 1760-1. [PMID: 16159992]